Yin and colleagues combine human genetics with mouse and hepatocyte models to support mARC1 inhibition as a therapy for MASLD and MASH 1. The whole-body Mtarc1 knockout data add to prior liver-targeted knockdown work, and the study strengthens the case for this target 1. We feel several clarifications could better guide translation to trials. One issue is the disease model. The liver benefits are shown after short exposure to a choline-deficient, amino acid-defined high-fat diet 1. This diet drives early steatohepatitis through oxidative stress and disturbed choline handling 2, but it does not capture long-term caloric excess, obesity, diabetes and mixed metabolic stress that dominate human MASLD 2. Fibrosis at 2 weeks is modest 1. The protection therefore seems closer to better tolerance of acute nutrient stress, especially in females, than to benefit in established fibrotic disease. Parallel work in Western-style or fructose-containing diets, with longer follow-up, insulin resistance and fibrosis end points, would more closely reflect the high-risk groups in which MTARC1 variants show the largest protective effect 3. Another concern is how large and precise the phenotype is. Key comparisons use small groups and no predefined primary outcome, power calculation or confidence intervals 1. Some histology and metabolite shifts are large but sit on wide variance. Focusing claims of protection on a small set of well powered outcomes, reportedwith effect sizes, confidence intervals and sex-stratified analyses, would make the signal easier to judge for drug development. A further point is the mismatch between mouse and human mechanistic readouts. Yin et al. report reduced fatty acid uptake, higher ApoB secretion and higher hepatic phosphatidylcholine and phosphatidylethanolamine in Mtarc1-deficient mouse hepatocytes, even under choline restriction 1. Human hepatocyte and population data instead suggest lower ApoB secretion and lower circulating phospholipids in carriers of protective MTARC1 alleles 4. Side-by-side studies in mouse and human hepatocytes under choline-replete conditions, using stable-isotope tracers to follow fatty acid flux and VLDL export, could help decide which readouts are reliable enough to take into early-phase trials. Finally, the current work relies on lifelong, whole-body Mtarc1 deletion, whereas Mtarc2 knockout causes marked extrahepatic toxicity 5. Adult-onset, liver-restricted mARC1 inhibition in obese or diabetic mice, with vascular, renal and neuromuscular safety readouts, will be essential to define a safe therapeutic window. Together, these steps would sharpen how MTARC1-directed therapies are matched to patient groups and safety monitoring. The authors have nothing to report. The authors have nothing to report. Generative AI (ChatGPT) was used solely to review and improve language clarity. All scientific content and interpretations are the authors' own work. The authors declare no conflicts of interest. This article is linked to Yin et al. papers. To view this article, visit https://doi.org/10.1111/liv.70507. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Wang et al. (Mon,) studied this question.